[Cardiovascular risk in children from 6 to 15 years with exogenous obesity]

Gabriela Virginia Escudero-Lourdes1, Luz Viridiana Morales-Romero, Concepción Valverde-Ocaña

  • 1Coordinación Clínica de Educación e Investigación en Salud, Hospital General de Zona 1, Instituto Mexicano del Seguro Social, San Luis Potosí, San Luis Potosí, México. gabriela.escudero@imss.gob.mx.

Insights

Cardiovascular risk is high in 60% of obese children, linked to lifestyle and diet. Early assessment using validated scales can prevent adult cardiovascular disease persistence.

Area of Science:

  • Pediatric Cardiology
  • Public Health
  • Preventive Medicine

Context:

  • Rising cardiovascular risk (CVR) is linked to lifestyle and diet.
  • Obese children represent a vulnerable population for developing cardiovascular disease.
  • This study was conducted in a secondary care unit of the Mexican Social Security Institute in San Luis Potosí, Mexico.

Purpose:

  • To assess the cardiovascular risk (CVR) in an obese pediatric population.
  • To identify key risk factors contributing to CVR in children.
  • To evaluate the utility of validated scales in pediatric CVR assessment.

Summary:

  • A cross-sectional study analyzed 100 obese children (ages 6-15) using Alústiza's scale.
  • 60% of children exhibited high CVR, with significant correlations found between CVR, HDL, and glucose levels.
  • Prevalence of hypercholesterolemia (46%) and hyperglycemia (34%) was noted, alongside family history of obesity and diabetes.

Impact:

  • Validated scales are effective tools for timely CVR assessment in children.
  • Early identification and intervention can mitigate the persistence of cardiovascular risk into adulthood.
  • Findings highlight the need for lifestyle interventions in pediatric obesity to reduce long-term cardiovascular burden.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
439
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K